Ionis Pharmaceuticals Inc. Sets Itself Up for Growth

Ionis Pharmaceuticals Inc. Sets Itself Up for Growth

Ionis Pharmaceuticals' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported its earnings. Nevertheless, the biotech is setting itself up for solid growth with two additional drugs under review by regulators.

Metric

Q3 2017

Continue reading

Source: Fool.com